Acadia Pharmaceuticals Inc. (ACAD)
Nasdaq · Healthcare · Biotechnology
$20.11+0.80%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $3.5B
- P/E (trailing)
- 9.0
- Forward P/E
- 22.6
- 52-week range
- $19.57 – $30.96
- 52-week change
- −7.60%
- EPS (trailing)
- $2.23
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $1.1B (+11.87%)
- Net income
- $391M
- Operating margin
- 9.8%
- Diluted EPS
- $2.30
- Free cash flow
- $105M
From the company’s annual report on SEC EDGAR.
About Acadia Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.
Headquarters: San Diego, United States · 796 employees · acadia.com